Healthcare

Image

North America Clinical Trial Imaging Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Published Report
  • Sep 2022
  • North America
  • 350 Pages
  • No of Tables: 88
  • No of Figures: 44

North America Clinical Trial Imaging Market, By Product and Services (Services and Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-ray, Ultrasound, Optical Coherence Tomography and Others), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Hematology and Others), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturers, Academic and Government Research Institutes and Others), Distributor (Direct Sales and Tender Sales) - Industry Trends and Forecast to 2029.

North America Clinical Trial Imaging Market

North America Clinical Trial Imaging Market Analysis and Insights

The increasing demand for imaging technology, followed by rise in the prevalence of chronic diseases due to rise in elderly population and strategic initiatives by market players such as product launch, advancement, acquisition and agreements are the factors that are expected to drive the market growth.

North America Clinical Trial Imaging Market

North America Clinical Trial Imaging Market

However, improper and unfavourable reimbursement scenarios for imaging devices and lack of well-defined standards in clinical trial imaging instruments are expected to restrain the market growth.

The rising technological progressions in clinical trial imaging for diagnosis and treatment of chronic diseases are expected to drive market growth. Data Bridge Market Research analyzes that the North America clinical trial imaging market will grow at a CAGR of 8.3% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customisable to 2019-2014)

Quantitative Units

Revenue in USD Million and Pricing in USD

Segments Covered

By Product and Services (Services and Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-ray, Ultrasound, Optical Coherence Tomography and Others), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Hematology and Others), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturers, Academic and Government Research Institutes and Others), Distributor (Direct Sales and Tender Sales)

Countries Covered

U.S., Canada, and Mexico

Market Players Covered

Navitas Life Sciences, Resonance Health Analytical Services, BioTelemetry, a Philips Company, ICON plc, Quotient Sciences, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group, and Invicro.LLC among others

Market Definition

Clinical trial is a process of developing new drugs. It is designed for potential treatment and its effects on humans. Before the commercialization of new drugs, extensive clinical testing is done to identify promising compounds, and safety tests are conducted to determine the possible risks.

In clinical trials, medical imaging plays a significant role in more accurate and effective results. Different imaging technologies may be used to elucidate and demonstrate the mechanistic actions of drugs. Clinical trial imaging is the process of clinical analysis and medical intervention by creating image representations of inner parts of the body. It has several different technologies which are used to view the human body to monitor, treat, and diagnose medical conditions.

In the coming future, important decisions related to clinical trial imaging on drug discovery will be made by individuals who not only understand the biopsy but can also use the clinical trial imaging tools and the knowledge they release to develop hypotheses and identify quality targets.

North America Clinical Trial Imaging Market Dynamics

Drivers

  • Rising R&D Expenditure

Imaging and pharma companies are continuously investing in R&D to offer innovative services for clinical trial imaging to customers and enhance their market presence. Medical imaging plays a dynamic role in clinical development. While the medical imaging industry is in a constant state of fluctuation due to implementation of new technologies in the market, the pharmaceutical and imaging industries continue to increase. This is attributed to enhanced investment in medical imaging companies along with mergers and acquisitions as well as the adoption of innovation in imaging technologies to support clinical trials for medical devices. Increasing R&D expenditure in pharmaceutical and biotechnological companies is fueling market growth.

This has encouraged the development of new products and high research-oriented programs organized in biopharmaceutical industries and a high preference for the studies of human genome. Rising expenditure on R&D activities also develops new drugs and therapies to treat chronic diseases that boost market growth. This helps the pharmaceutical and biotechnological companies in the development of new technologies in the category of imaging clinical trials therefore, rising R&D expenditure is expected to drive the market growth.

  • Increasing Number of Contract Research Organizations (CROs)

Contract Research Organization (CRO) is an organization that gives support for clinical trials and other research services to imaging and pharmaceutical industries in the form of outsourced pharmaceutical research services in terms of both drugs and medical devices. CRO helps imaging and pharmaceutical industries with the drug development process to reduce the cost and initiate the process of bringing clinical trials to develop the drug for a particular disease segment by using clinical trial imaging and other processes to overcome capacity gaps of the in-house research team for pharmaceutical and clinical research.

CRO is the backbone of the clinical trial industry. CROs manage all aspects of a clinical trial. In the clinical trial services, CRO offers various drug development services, such as:

A huge number of CROs are engaged in monitoring the drug development process such as PAREXEL (U.S.), PRA Health Sciences (U.S.), Labcorp (U.S.), PPD (U.S.), Syneos Health (U.S.), ICON plc (Ireland), Envigo (U.K.), Charles River (U.S.), and SGS (Switzerland) among others. These are some CROs that are engaged to give support for clinical trials and other research services to the imaging and pharmaceutical industries. The increasing number of CROs is expected to drive market growth.

Opportunities

  • Rise in Healthcare Expenditure

Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure.

Growing healthcare expenditure is also beneficial for further growth in economic and healthcare sector, and it is primarily fruitful as it significantly affects the development of better and advanced medical products in the market. Therefore, the surge in healthcare expenditure is expected to create a greater opportunity for the market.

  • Strategic Initiatives by Market Players

The demand for clinical trial imaging is increasing in the market owing to the increased levels of R&D along with the growth of clinical trial imaging market aided by the desire for innovative medications. Thus, the top market players have implemented a new strategy by developing new products and collaborating with other market players to improve business operations and profitability.

For instance,

  • In June 2022, Parexel, a leading global CRO, announced the launch of its Community Alliance Network, a novel program further integrating clinical research into the community healthcare setting to better serve patients and in turn create further opportunities for increased diversity in clinical trials. CVS Health, the leading health care solutions company, and Javara, the leading Integrated Research Organization, have joined the network as inaugural members, opening the door to community-based research sites and increasing access to new patient populations to support trial delivery for Parexel’s biopharmaceutical customers.
  • In February 2020, ICON plc acquired MedPass International, a European medical devices CRO, reimbursement, and regulatory consultancy. This acquisition has reportedly helped in the expansion of the medical device and diagnostic research services of ICON in Europe.

These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping them grow and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may act as an opportunity for market growth.

Restraints/Challenges

  • High-Risk Radiation Causing Diseases

In clinical medical imaging, radiation is absorbed by the body which can harm the molecular structures inside the patient’s body. High doses of radiation can affect human cells including loss of hair, skin burns, and increased incidence of cancer. The estimated risk of developing fatal cancer is one in 2000 after going through a radiation dose of 10 mSv in a CT scan.

For instance,

  • According to Radiological Society of North America (RSNA), 1% to 2% of all cancers in the U.S. are caused by CT scans and the American Cancer Society identified CT scans and X-rays as one of the reasons for breast cancer, brain cancer, and other cancers
  • According to Center for Disease Control and Prevention, exposure to high levels of radiation results in acute radiation syndrome. The amount of radiation that a person's body absorbs is called the radiation dose.

The high-risk radiation that occurs, would decrease the usage and sale of clinical trial imaging devices, thereby affecting the credibility of manufacturers involved in this market. Therefore, the high-risk radiation-causing diseases are expected to restrain the market growth.

  • Strict Regulatory Policies

The healthcare industry is regulated by a structure of laws, and rules & regulations that are extensive and complex.

For instance,

  • In April 2018, the U.S. FDA released updated Guidance for Clinical Trial Imaging Endpoint Process Standards for the industry which includes the quality of imaging data obtained in clinical trials
  • Biotechnology and pharmaceutical industries need to take first approval from the FDA for the process of drug development. They have to submit an Investigational New Drug (IND) application to the FDA before beginning clinical research.

COVID-19 Impact on the North America Clinical Trial Imaging Market

Diagnostic imaging services have been time-consuming and complicated by the need for strict infection control and prevention practices developed to contain the risk of transmission and protect healthcare personnel. Hence, the decision to image suspected patients or COVID-19-positive patients is based on their impact on the improvement of patient status. The American College of Radiology (ACR), does not recommend Computed Tomography (CT) as a first-line diagnostic test for COVID-19 patients and limits computed tomography utility to symptomatic and hospitalized patients with specific clinical indications.

Recent Developments

  • In January 2022, Clario partnered with XingImaging, a radiopharmaceutical production and Positron Emission Tomography (PET) acquisition company, to deliver PET imaging clinical trials for testing novel therapeutics in China. The partnership offers to share the joint resources and neuroscience experts of Clario and XingImaging to expedite the start-up of clinical trials and drug discovery in China.
  • In November 2021, Clario was formed. ERT and Bioclinica, merged to form Clario. The formation of the new company resulted in the distribution of clinical imaging software and services and rise in sales.

North America Clinical Trial Imaging Market Scope

North America clinical trial imaging market is segmented into five segments based on product and services, modality, application, end user, and distributor. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

  • Services
  • Software

Based on product and services, the market is segmented into services and software.

Modality

  • Computed Tomography
  • Magnetic Resonance Imaging
  • Echocardiography
  • Nuclear Medicine
  • Positron Emission Tomography
  • X-ray
  • Ultrasound
  • Optical Coherence Tomography
  • Others

Based on modality, the market is segmented into computed tomography, magnetic resonance imaging, echocardiography, nuclear medicine, positron emission tomography, X-ray, ultrasound, optical coherence tomography and others.

Application

  • Oncology
  •  Neurology
  •  Cardiology
  •  Endocrinology
  •  Dermatology
  •  Hematology
  •  Others

Based on application, the market is segmented into oncology, neurology, cardiology, endocrinology, dermatology, hematology and others.

End user

  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Medical Device Manufacturers
  • Academic and Government Research Institutes
  • Others

Based on end user, the market is segmented into contract research organizations, pharmaceutical & biotechnology companies, medical device manufacturers, academic and government research institutes and others.

Distributor

  • Direct Sales
  •  Tender Sales

Clinical Trial Imaging Market

Based on distributor, the market is segmented into direct sales and tender sales.

North America Clinical Trial Imaging Market Regional Analysis/Insights

North America clinical trial imaging market is analyzed, and market size insights and trends are provided by regions, product and services, modality, application, end user, and distributor as referenced above.

The countries covered in this market report are the U.S., Canada, and Mexico. The U.S. is expected to dominate the market due to a rise in the incidence of cancer, demand for non-invasive medical imaging, growth of technological innovations in clinical trial imaging, and a rise in R&D activities.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Clinical Trial Imaging Market Share Analysis

North America clinical trial imaging market competitive landscape provides details on the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, the North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the North America clinical trial imaging market.

Some of the major players operating in the market are Navitas Life Sciences, Resonance Health Analytical Services, BioTelemetry, a Philips Company, ICON plc, Quotient Sciences, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group, and Invicro.LLC among others.


SKU-

TABLE 1 COST OF CLINICAL TRIAL PHASE 2 AND PHASE 3

TABLE 2 HUGE R&D COST IN THE U.S. FOR DIFFERENT PHASES

TABLE 3 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA SOFTWARE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA COMPUTED TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA MAGNETIC RESONANCE IMAGING IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA ECHOCARDIOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA NUCLEAR MEDICINE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA POSITRON EMISSION TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA X-RAY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA ULTRASOUND IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA OPTICAL COHERENCE TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA CONTRACT RESEARCH ORGANIZATION IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA MEDICAL DEVICE MANUFACTURERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA DIRECT SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA TENDER SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 45 NORTH AMERICA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 46 NORTH AMERICA NEUROLOGY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 47 NORTH AMERICA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION,2020-2029 (USD MILLION)

TABLE 48 NORTH AMERICA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 49 NORTH AMERICA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 50 NORTH AMERICA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 51 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 NORTH AMERICA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 53 U.S. CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 54 U.S. SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 55 U.S. CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 56 U.S. CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 57 U.S. ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 58 U.S. NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 59 U.S. ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 60 U.S. CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 61 U.S. DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 62 U.S. HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 63 U.S. CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 U.S. CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 65 CANADA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 66 CANADA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 67 CANADA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 68 CANADA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 69 CANADA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 70 CANADA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 71 CANADA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 72 CANADA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 CANADA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 74 CANADA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 75 CANADA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 CANADA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 77 MEXICO CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 78 MEXICO SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 79 MEXICO CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 80 MEXICO CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 81 MEXICO ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 82 MEXICO NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 83 MEXICO ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 84 MEXICO CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 85 MEXICO DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 86 MEXICO HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 87 MEXICO CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 88 MEXICO CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The North America Clinical Trial Imaging Market is expected to grow at a CAGR of 8.3% during the forecast by 2029.
The key opportunities in the North America Clinical Trial Imaging Market are the Rise in Healthcare Expenditure & Strategic Initiatives by Market Players.
The major players in the North America Clinical Trial Imaging Market are Navitas Life Sciences, Resonance Health Analytical Services, BioTelemetry, a Philips Company, ICON plc, Quotient Sciences, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group, and Invicro.LLC among others.
The countries covered in the North America Clinical Trial Imaging Market are U.S., Canada, and Mexico.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials